Absci (NASDAQ:ABSI) Trading 1% Higher

Absci Co. (NASDAQ:ABSIGet Rating)’s share price traded up 1% during trading on Tuesday . The company traded as high as $3.25 and last traded at $3.12. 466,859 shares were traded during trading, a decline of 0% from the average session volume of 468,491 shares. The stock had previously closed at $3.09.

Absci Stock Performance

The company has a market cap of $288.27 million, a PE ratio of -2.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.03, a current ratio of 6.71 and a quick ratio of 6.71. The business has a 50-day moving average of $2.48 and a 200 day moving average of $3.12.

Absci (NASDAQ:ABSIGet Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The firm had revenue of $2.37 million for the quarter, compared to analysts’ expectations of $1.79 million. Absci had a negative net margin of 1,960.28% and a negative return on equity of 33.62%. Equities research analysts anticipate that Absci Co. will post -1.13 EPS for the current fiscal year.

Institutional Trading of Absci

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Metropolitan Life Insurance Co NY purchased a new stake in Absci in the first quarter worth about $33,000. Two Sigma Advisers LP purchased a new stake in shares of Absci during the third quarter worth about $34,000. Ameritas Investment Partners Inc. grew its position in shares of Absci by 305.3% during the first quarter. Ameritas Investment Partners Inc. now owns 4,312 shares of the company’s stock worth $36,000 after purchasing an additional 3,248 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Absci during the third quarter worth about $42,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Absci during the second quarter worth about $43,000. Hedge funds and other institutional investors own 47.59% of the company’s stock.

Absci Company Profile

(Get Rating)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process.

Read More

Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.